George Mason CLIA Lab to Use Aushon Arrayer to Study PGx-Based Cancer Rxs | GenomeWeb
NEW YORK (GenomeWeb News) — George Mason University will use an Aushon Biosystems 2470 arrayer to study targeted cancer treatments, the company said today.
George Mason has installed the 2470 in a CAP-CLIA laboratory that focuses on clinical trials for cancer treatments based on protein expression profiles.
Financial terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.